Novel medicines focused on the BIG Axis

We are advancing a rich pipeline of innovative therapies across two divisions.

Our Affiliates pipeline

Our Affiliates pipeline includes seven clinical-stage platforms, including one product that has been cleared by the FDA and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programs. View our latest corporate deck.

Brain/Nervous System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
Akili
Digital Medicine for CNS Disorders
35.1%

Cognitive Interference Processing

Founded by PureTech Health as part of its cognition initiative, Akili is combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. Akili is pioneering the development of treatments with direct therapeutic activity, delivered not through a traditional pill but via a high-quality action video game experience. Akili is a leader in the digital therapeutics field and is a founding member of the Digital Therapeutic Alliance.

MORE
Karuna
Selective Muscarinic Receptor Targeting for CNS Disorders
*31.6%

Selective Muscarinic Receptor Agonists

Founded by PureTech Health, Karuna is targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease psychosis, as well as pain. KarXT (Karuna-XanomelineTrospium) is Karuna’s lead investigational product candidate. It consists of xanomeline, a novel muscarinic acetylcholine receptor agonist that has demonstrated efficacy in placebo-controlled human trials in schizophrenia and Alzheimer’s disease, and trospium chloride, an FDA approved and well-established muscarinic receptor antagonist that has been shown not to measurably cross the bloodbrain barrier. KarXT is designed to selectively stimulate M1/M4 muscarinic receptors in the brain without stimulating muscarinic receptors in peripheral tissues to significantly improve tolerability.

MORE
Sonde
Vocal Biomarkers to Monitor and Manage CNS Disorders
55.8%

Vocal Biomarkers

Founded by PureTech Health, Sonde is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. Sonde’s proprietary technology works by sensing and analyzing subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in just seconds. To date, Sonde has collected voice data from over 14,000 subjects as a part of the ongoing validation of its platform, and it has also initiated research and development to expand its proprietary technology into Alzheimer’s, respiratory, and cardiovascular disease, as well as other health and wellness conditions.

MORE

Immune System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
resTORbio
Immunotherapies for Aging-Related Diseases
**27.8%

Selective mTORC1 Inhibitors

Founded by PureTech Health, resTORbio is developing innovative medicines that target the biology of aging to prevent or treat aging-related disorders. resTORbio’s lead program selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular, and central nervous systems. resTORbio’s lead product candidate, RTB101, is an oral, selective, and potent inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Inhibition of TORC1 has been observed to extend lifespan and healthspan in aging preclinical species and to improve immune, cardiac and neurologic functions, suggesting potential benefits in several aging-related diseases.

MORE
Follica
Regenerative Biology Platform for Androgenetic Alopecia
77.9%

Abrasion Induced Neogenesis

Founded by PureTech Health, Follica’s regenerative biology platform is based on seminal findings from the University of Pennsylvania that demonstrated the creation of skin organs (hair follicles) in adult mammals after abrasion. This technology is being applied to treat androgenetic alopecia and other aesthetic-related indications. Follica’s technology is the first, to PureTech’s knowledge, designed to create new follicles and hair through disruption of the skin, followed by treatment to enhance the effect. Follica completed three human clinical studies of patients with androgenetic alopecia to demonstrate hair growth and new hair follicle formation and has been optimizing its device and conducting tests in androgenetic alopecia and other aesthetic indications.

MORE
Vedanta
Microbiome-Derived Modulators for Immune and Infectious Disease
57.4%

Microbiome-Derived Immune Modulators

Our affiliate Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on a rationally-defined consortium of human microbiome-derived bacteria. Our product candidates are designed to modulate pathways of interaction between the human microbiome and the host immune system to treat serious diseases. As a leader in the field of defined microbial consortia for autoimmune disorders, infections, and immuno-oncology, we are advancing a pipeline of product candidates that seek to address these serious diseases. 

MORE
Alivio
Targeted Disease Immunomodulation for Acute and Chronic Inflammatory Disorders
82.8%

Inflammation-Targeting Technology

Founded by PureTech Health, Alivio Therapeutics is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves tuning the immune system exclusively at the site of disease in the body, with minimal impact on the rest of the immune system. This long sought-after approach has the potential to treat a range of chronic and acute inflammatory disorders, including ones that would otherwise be difficult to treat. Alivio’s proprietary inflammation-targeting platform is designed to administer therapeutics to the sites of inflammation, while sparing normal tissues from unnecessary drug exposure.  The technology is also engineered to respond dynamically to inflammation, releasing the enclosed therapeutics based on the degree of inflammation present. 

MORE
Vor
Unleashing Targeted Immunotherapy for Heme Malignancies
30.2%

Targeted Therapies in Cancer

Founded by PureTech Health, Vor is developing cell therapies with broad potential for treating cancer. Vor’s key differentiation is a focus on technologies that can selectively target cancer cells without impacting normal cells. Engineered cells, such as chimeric antigen receptor (CAR) T cells, are now FDA-approved drugs for treating hematologic malignancies. However, these and similar technologies target both cancer and normal cells, causing substantial toxicities and limiting their potential. Vor is taking a fundamentally novel approach for targeting cancer selectively by developing engineered hematopoietic stem cells (HSCs). Vor’s engineered HSCs generate healthy, functional cells that are protected from depletion by cancer-targeted therapies.

MORE

GI System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
Gelesis
Hydrogel Platform Technology for GI-Related Chronic Diseases
19.7%

Proprietary Hydrogel Platform Technology

Our affiliate Gelesis is a biotechnology company developing a novel category of therapies for GI-related chronic diseases. The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Constipation (CIC). 

MORE
Entrega
Engineered Hydrogels to Enable Oral Delivery of Peptides
73.9%

Oral Administration of Biologics – Novel Hydrogel

Founded by PureTech Health, Entrega is focused on the oral delivery of biologics, vaccines, and other drugs that are otherwise not efficiently absorbed when taken orally. The vast majority of biologic drugs (including peptides, proteins, and other macromolecules) are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Oral administration thus represents an ideal delivery approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.

MORE

Brain / Nervous System

Akili
Digital Medicine for CNS Disorders
35.1%
Filing

Cognitive Interference Processing

Founded by PureTech Health as part of its cognition initiative, Akili is combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. Akili is pioneering the development of treatments with direct therapeutic activity, delivered not through a traditional pill but via a high-quality action video game experience. Akili is a leader in the digital therapeutics field and is a founding member of the Digital Therapeutic Alliance.

MORE
Karuna
Selective Muscarinic Receptor Targeting for CNS Disorders
*31.6%
2

Selective Muscarinic Receptor Agonists

Founded by PureTech Health, Karuna is targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease psychosis, as well as pain. KarXT (Karuna-XanomelineTrospium) is Karuna’s lead investigational product candidate. It consists of xanomeline, a novel muscarinic acetylcholine receptor agonist that has demonstrated efficacy in placebo-controlled human trials in schizophrenia and Alzheimer’s disease, and trospium chloride, an FDA approved and well-established muscarinic receptor antagonist that has been shown not to measurably cross the bloodbrain barrier. KarXT is designed to selectively stimulate M1/M4 muscarinic receptors in the brain without stimulating muscarinic receptors in peripheral tissues to significantly improve tolerability.

MORE
Sonde
Vocal Biomarkers to Monitor and Manage CNS Disorders
55.8%
1

Vocal Biomarkers

Founded by PureTech Health, Sonde is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. Sonde’s proprietary technology works by sensing and analyzing subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in just seconds. To date, Sonde has collected voice data from over 14,000 subjects as a part of the ongoing validation of its platform, and it has also initiated research and development to expand its proprietary technology into Alzheimer’s, respiratory, and cardiovascular disease, as well as other health and wellness conditions.

MORE

Immune System

resTORbio
Immunotherapies for Aging-Related Diseases
**27.8%
3

Selective mTORC1 Inhibitors

Founded by PureTech Health, resTORbio is developing innovative medicines that target the biology of aging to prevent or treat aging-related disorders. resTORbio’s lead program selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular, and central nervous systems. resTORbio’s lead product candidate, RTB101, is an oral, selective, and potent inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Inhibition of TORC1 has been observed to extend lifespan and healthspan in aging preclinical species and to improve immune, cardiac and neurologic functions, suggesting potential benefits in several aging-related diseases.

MORE
Follica
Regenerative Biology Platform for Androgenetic Alopecia
77.9%
2

Abrasion Induced Neogenesis

Founded by PureTech Health, Follica’s regenerative biology platform is based on seminal findings from the University of Pennsylvania that demonstrated the creation of skin organs (hair follicles) in adult mammals after abrasion. This technology is being applied to treat androgenetic alopecia and other aesthetic-related indications. Follica’s technology is the first, to PureTech’s knowledge, designed to create new follicles and hair through disruption of the skin, followed by treatment to enhance the effect. Follica completed three human clinical studies of patients with androgenetic alopecia to demonstrate hair growth and new hair follicle formation and has been optimizing its device and conducting tests in androgenetic alopecia and other aesthetic indications.

MORE
Vedanta
Microbiome-Derived Modulators for Immune and Infectious Disease
57.4%
2

Microbiome-Derived Immune Modulators

Our affiliate Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on a rationally-defined consortium of human microbiome-derived bacteria. Our product candidates are designed to modulate pathways of interaction between the human microbiome and the host immune system to treat serious diseases. As a leader in the field of defined microbial consortia for autoimmune disorders, infections, and immuno-oncology, we are advancing a pipeline of product candidates that seek to address these serious diseases. 

MORE
Alivio
Targeted Disease Immunomodulation for Acute and Chronic Inflammatory Disorders
82.8%
Preclinical

Inflammation-Targeting Technology

Founded by PureTech Health, Alivio Therapeutics is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves tuning the immune system exclusively at the site of disease in the body, with minimal impact on the rest of the immune system. This long sought-after approach has the potential to treat a range of chronic and acute inflammatory disorders, including ones that would otherwise be difficult to treat. Alivio’s proprietary inflammation-targeting platform is designed to administer therapeutics to the sites of inflammation, while sparing normal tissues from unnecessary drug exposure.  The technology is also engineered to respond dynamically to inflammation, releasing the enclosed therapeutics based on the degree of inflammation present. 

MORE
Vor
Unleashing Targeted Immunotherapy for Heme Malignancies
30.2%
Preclinical

Targeted Therapies in Cancer

Founded by PureTech Health, Vor is developing cell therapies with broad potential for treating cancer. Vor’s key differentiation is a focus on technologies that can selectively target cancer cells without impacting normal cells. Engineered cells, such as chimeric antigen receptor (CAR) T cells, are now FDA-approved drugs for treating hematologic malignancies. However, these and similar technologies target both cancer and normal cells, causing substantial toxicities and limiting their potential. Vor is taking a fundamentally novel approach for targeting cancer selectively by developing engineered hematopoietic stem cells (HSCs). Vor’s engineered HSCs generate healthy, functional cells that are protected from depletion by cancer-targeted therapies.

MORE

GI System

Gelesis
Hydrogel Platform Technology for GI-Related Chronic Diseases
19.7%
FDA Cleared

Proprietary Hydrogel Platform Technology

Our affiliate Gelesis is a biotechnology company developing a novel category of therapies for GI-related chronic diseases. The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Constipation (CIC). 

MORE
Entrega
Engineered Hydrogels to Enable Oral Delivery of Peptides
73.9%
Preclinical

Oral Administration of Biologics – Novel Hydrogel

Founded by PureTech Health, Entrega is focused on the oral delivery of biologics, vaccines, and other drugs that are otherwise not efficiently absorbed when taken orally. The vast majority of biologic drugs (including peptides, proteins, and other macromolecules) are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Oral administration thus represents an ideal delivery approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.

MORE

*PureTech owns 7,395,397 shares of Karuna, which is equal to approximately 31.6% of the outstanding shares of Karuna.

**PureTech owns 9,800,396 shares of resTORbio, which is equal to approximately 27.8% of the outstanding shares of resTORbio.

 

Collaborating with Industry Pioneers Across Our Affiliates and Internal Pipelines

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

DISCOVERY REINVENTED

  • Aging related immune disorders
  • Gut/Immune Ecosystem
  • Severe and Chronic Mental Health